References
- Raoult D, Marrie T. Q fever. Clin Infect Dis 1995; 20: 489–96
- Maurin M, Raoult D. Q fever. Clin Microbiol Rev 1999; 12: 518–53
- Dupont HT, Raoult D, Brouqui P. Epidemiological features and clinical presentation of acute Q fever in hospitalized patients: 323 French cases. Am J Med 1992; 93: 427–34
- Marrie TJ. Coxiella burnetii pneumonia. Eur Resp J 2003; 21: 713–9
- Gikas A, Kofteridis DP, Manios A, Pediaditis J, Tselentis Y. Newer macrolides as empirical treatment of acute Q fever infection. Antimicrob Agents Chemother 2001; 45: 3644–6
- Fournier PE, Marrie TJ, Raoult D. Diagnosis of Q fever. J Clin Microbiol 1998; 36: 1823–34
- Cowley R, Fernandez F, Freemantle W, Rutter D. Enzyme immunoassay for Q fever: comparison with complement fixation and immunofluorescence tests and dot immunobloting. J Clin Microbiol 1992; 30: 2451–5
- Waag D, Chulay J, Marrie T, England M, Williams J. Validation of an enzyme immunoassay for serodiagnosis of acute Q fever. Eur J Clin Microbiol Infect Dis 1995; 14: 421–7
- Rolain JM, Maurin M, Raoult D. Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii. Antimicrob Agents Chemother 2001; 45: 301–2
- Gikas A, Spyridaki I, Scoulica E, Psaroulaki A, Tselentis Y. In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibility to quinolones, doxycycline, and clarithromycin. Antimicrob Agents Chemother 2001; 45: 3276–8
- Kuzman I, Schoenwald S, Čulig J, Orešković K, Zrnić T. Efficacy of azithromycin in the treatment of Q fever: a retrospective study. In: Programme and abstracts of the Fourth International Conference on macrolides, azalides, streptogramins and ketolides. BarcelonaSpain. 1998, Abstract 4.31.
- Keating GM, Scott LJ. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs 2004; 64: 2347–77
- Balfour JA, Wiseman LR. Moxifloxacin. Drugs 1999; 57: 363–74
- Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clin Drug Invest 1999; 17: 365–87
- Bloudeau JM, Felmingham D. In vitro and in vivo activity of moxifloxacin against community respiratory tract pathogens. Clin Drug Invest 1999; 18: 57–78
- Williams JH. Fluoroquinolones for respiratory infections. Chest 2001; 120: 1771–5